ISSN 1662-4009 (online)

ey0020.11-3 | Improving Access to Healthcare in Pediatric Endocrinology and Diabetes | ESPEYB20

11.3. Ten-year experience of a global and freely accessible e-Learning website for pediatric endocrinology and diabetes

SM Ng , E Kalaitzoglou , A Utari , C van Wijngaard-de Vugt , M Donaldson , JI Wolfsdorf , AM Boot , S Drop

Brief summary: The authors describe the various applications of the content of ESPE’s e-learning website that has been expanding greatly over the last 10 years. The program includes a Limited Resource Setting module that was developed in 2017 and has been translated into French, Spanish, Swahili, and Chinese.This interesting article retraces the successful development of ESPE’s e-learning program since 2012. Thanks to the tenacity and involveme...

ey0015.5-1 | New and repurposed therapies | ESPEYB15

5.1 Burosumab Therapy in Children with X-Linked Hypophosphatemia

TO Carpenter , MP Whyte , EA Imel , AM Boot , W Hogler , A Linglart , R Padidela , W Van't Hoff , M Mao , CY Chen , A Skrinar , E Kakkis , J San Martin , AA Portale

To read the full abstract: N Engl J Med 2018;378:1987-1998FGF-23 is the primary regulator of phosphate homeostasis and acts by inhibiting phosphate reabsorption in the kidney (1). Loss-of-function mutations in the gene encoding phosphate-regulating endopeptidase homolog X-linked (PHEX) results in excess circulating FGF-23, which impairs renal phosphate reabsorption causing hypophosphatemia...